Three groups of 8 Japanese males are given single ascending doses of ASP1707 or placebo to assess the safety and tolerability, and to evaluate how it is absorbed, metabolized and distributed through the body.
The first group receives the lowest dose while the last group receives the highest dose. ASP1707 or matching placebo is administered as a single dose under fasted conditions. Screening takes place from Day -22 to Day -2. Subjects are admitted to the clinic on Day -1 and remain until Day 5. An end of study visit (ESV) takes place 7-14 days after discharge. Escalation to the next higher dose takes place after review of the safety and tolerability data from the previous dose. Safety assessments are performed throughout the study. Plasma and urine samples are collected for pharmacokinetics (PK) analysis. Serum samples are collected for pharmacodynamic (PD) analysis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
24
Parexel Early Phase
Harrow, United Kingdom
Safety and tolerability measured by Adverse events (AE)
Time frame: Day -2 to ESV (up to Day 19)
Safety and tolerability measured by physical examination (PE)
Time frame: Day -2 to ESV (up to Day 19)
Safety and tolerability measured by vital signs (VS)
Time frame: Day -2 to ESV (up to Day 19)
Safety and tolerability measured by laboratory tests
Time frame: Day -2 to ESV (up to Day 19)
Safety and tolerability measured by 12 lead electrocardiogram (ECG)
Time frame: Day -2 to ESV (up to Day 19)
PK profile of single ascending doses of ASP1707 in plasma
area under the plasma concentration - time curve (AUC) extrapolated to time = infinity (AUCinf), AUC from time of dosing until last measurable concentration (AUClast), time to reach quantifiable concentrations (tlag), maximum concentration (Cmax), time to attain Cmax (tmax), terminal elimination half-life (t1/2), apparent volume of distribution (Vz/F), apparent clearance (CL/F)
Time frame: Days 1 to 5
PK profile of single ascending doses of ASP1707 in urine
amount excreted unchanged into urine (Ae) from time of dosing until last measurable concentration (Aelast), Ae extrapolated to time = infinity (Aeinf), Ae from time of dosing until last measurable concentration as percentage of total dose (Aelast%), Ae extrapolated to time = infinity as percentage of total dose (Aeinf%), renal clearance (CLR)
Time frame: Days 1 to 5
Pharmacodynamics of Testosterone (T)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
measured by minimum concentration (Cmin), time to attain Cmin (tmin), maximal %Reduction T only: number and percentage of subjects with T castration level (= T \< 500 pg/mL) after single dose, time of onset and offset of T \< 500 pg/mL after single dose, duration of T \<500 pg/mL after single dose
Time frame: Day -1 to ESV
Pharmacodynamics of Luteinizing Hormone (LH)
measured by minimum concentration (Cmin), time to attain Cmin (tmin), maximal %Reduction T only: number and percentage of subjects with T castration level (= T \< 500 pg/mL) after single dose, time of onset and offset of T \< 500 pg/mL after single dose, duration of T \<500 pg/mL after single dose
Time frame: Day -1 to ESV
Pharmacodynamics of Follicle-Stimulating Hormone (FSH) levels
measured by minimum concentration (Cmin), time to attain Cmin (tmin), maximal %Reduction T only: number and percentage of subjects with T castration level (= T \< 500 pg/mL) after single dose, time of onset and offset of T \< 500 pg/mL after single dose, duration of T \<500 pg/mL after single dose
Time frame: Day -1 to ESV